
Our sister site, Drug Delivery Business News, spoke with Sayer recently about the developments at the company over the last 12 months, as well as what may come in the next 12 months and beyond.
In 2024, the company became the first to receive FDA approval for an over-the-counter (OTC) continuous glucose monitor (CGM), the Stelo device. Meanwhile, Dexcom continues to advance its G7 platform, its latest-generation CGM offering. In 2024, the company launched a new capability, as G7 can now connect directly to the Apple Watch in the U.S.
The CEO discussed some of the new offerings on the horizon at the San Diego-based continuous glucose monitor (CGM) maker. That includes new partnerships, new form factors and the addition of generative AI to the company’s sensors.
“We’re very excited about all those things going on,” Sayer told Drug Delivery Business News in a recent interview. “Our [outside the U.S.] opportunities are still really big and we continued our U.S. growth and margin expansion. 2025 is really shaping up to be a good year for us.”
“[I just like to] make everybody remember what a great position this company is in. We’ve accomplished a lot. We have much, much more to do.”
Get the full story at our sister site, Drug Delivery Business News.